Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LSTA Lisata Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: LSTA
Price (delayed)
$2.66
Market cap
$22.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.3
Enterprise value
$2.65M
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely
Highlights
The EPS has grown by 7% YoY and by 4.2% from the previous quarter
The net income has grown by 3.7% YoY and by 3.4% from the previous quarter
Lisata Therapeutics's quick ratio has increased by 22% from the previous quarter but it has decreased by 14% YoY
LSTA's equity is down by 41% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of LSTA
Market
Valuations
Earnings
Shares outstanding
8.6M
Market cap
$22.87M
Enterprise value
$2.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.9
Price to sales (P/S)
22.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.65
Revenue
$1M
Gross profit
$1M
Operating income
-$21.66M
Net income
-$19.31M
EBIT
-$20.27M
EBITDA
-$20.1M
Free cash flow
-$17.76M
Per share
Balance sheet
Liquidity
EPS
-$2.3
EPS diluted
-$2.3
Free cash flow per share
-$2.06
Book value per share
$2.94
Revenue per share
$0.12
TBVPS
$3.35
Total assets
$28.98M
Total liabilities
$3.88M
Debt
$0
Equity
$25.36M
Working capital
$24.81M
Debt to equity
0
Current ratio
7.52
Quick ratio
6.98
Net debt/EBITDA
1.01
Margins
Efficiency
Dividend
EBITDA margin
-2,009.9%
Gross margin
100%
Net margin
-1,930.8%
Operating margin
-2,165.5%
Return on assets
-53.4%
Return on equity
-60.9%
Return on invested capital
-197%
Return on capital employed
-80.5%
Return on sales
-2,027%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LSTA stock price
How has the Lisata Therapeutics stock price performed over time
Intraday
2.18%
1 week
-0.75%
1 month
10.37%
1 year
-13.64%
YTD
-10.74%
QTD
13.19%
Financial performance
How have Lisata Therapeutics's revenue and profit performed over time
Revenue
$1M
Gross profit
$1M
Operating income
-$21.66M
Net income
-$19.31M
Gross margin
100%
Net margin
-1,930.8%
LSTA's operating income is up by 15% year-on-year and by 3.4% since the previous quarter
The net income has grown by 3.7% YoY and by 3.4% from the previous quarter
The operating margin has grown by 3.4% from the previous quarter
The net margin has grown by 3.4% from the previous quarter
Price vs fundamentals
How does LSTA's price correlate with its fundamentals
Growth
What is Lisata Therapeutics's growth rate over time
Valuation
What is Lisata Therapeutics stock price valuation
P/E
N/A
P/B
0.9
P/S
22.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.65
The EPS has grown by 7% YoY and by 4.2% from the previous quarter
LSTA's price to book (P/B) is 50% higher than its 5-year quarterly average of 0.6 and 13% higher than its last 4 quarters average of 0.8
LSTA's equity is down by 41% YoY and by 14% from the previous quarter
Efficiency
How efficient is Lisata Therapeutics business performance
The return on invested capital has dropped by 113% year-on-year and by 36% since the previous quarter
LSTA's ROE has plunged by 53% YoY and by 10% from the previous quarter
Lisata Therapeutics's return on assets has decreased by 49% YoY and by 10% QoQ
The ROS has grown by 2.5% from the previous quarter
Dividends
What is LSTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LSTA.
Financial health
How did Lisata Therapeutics financials performed over time
The company's total assets fell by 40% YoY and by 17% QoQ
The total liabilities has contracted by 32% from the previous quarter and by 29% YoY
The debt is 100% less than the equity
LSTA's equity is down by 41% YoY and by 14% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.